surprisingly well-tolerated clinical molecule

Ph. III candidate in SCLC (4 mg IV QW)

from aerospace compound phenotypic screen

J. Med. Chem., May 27, 2021

EpicentRx Inc., La Jolla, CA


The EpiCentRx Myc and CD47 downregulating molecule with a range of proposed mechanisms, RRx-001, is a Ph. III clinical candidate with an eyebrow-raising chemical structure that originated from an even…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: